Improving drug delivery for pancreatic cancer treatment
Official title: Stromal targeting to improve the efficacy of systemically administered drugs for pancreatic ductal adenocarcinomas
Funded at Purdue University · NIH-10981743 · Data updated 2026-11-12
This study is looking at a new way to make treatments for pancreatic cancer work better by using a special method to deliver a helpful enzyme right into the tumor, which might help other medicines reach the cancer cells more easily, and it’s designed for patients who are facing this tough disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $599,474 |
| NIH project number | 1R01CA283394-01A1 |
| Project ID | NIH-10981743 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking new treatment options.
✕Less likely to help
Patients with other types of cancer or those who are not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of treatments for pancreatic ductal adenocarcinoma (PDAC) by targeting the dense stroma surrounding tumors. The approach involves developing a controlled release system for delivering hyaluronidase directly into the tumor, which may help break down barriers that prevent drugs from reaching cancer cells. By using advanced imaging techniques, the study aims to monitor how these therapies affect blood flow and drug distribution within the tumor. This could lead to more effective treatment options for patients suffering from this aggressive form of cancer.
Why it matters
Potential benefit: If successful, this research could significantly improve the delivery and effectiveness of cancer treatments for patients with pancreatic ductal adenocarcinoma.
How similar studies have gone: Previous research has shown promise in using stromal targeting therapies for other cancers, indicating potential success for this novel approach in pancreatic cancer.
Where this research is happening
-
Purdue University
West Lafayette, United States Active
Researchers
- Principal investigator: Solorio, Luis — Purdue University
- Study coordinator: Solorio, Luis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.